Key facts
- It has raised $420K across 1 recorded rounds; the latest was Early Stage VC in Feb 2026.
- Notable investors include FirstMile Ventures.
- OncoPatch has filed 1 Form D with the SEC, most recently Dec 2025 ($419K sold to 5 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for OncoPatch
Funding rounds
1 roundsAbout OncoPatch
Developer of a single-use skin cancer treatment patch designed to provide a non-invasive local treatment option for non-melanoma skin cancer. The company develops a patch that delivers low-energy beta radiation directly to basal and squamous cell carcinoma lesions with shallow tissue penetration to limit exposure of surrounding healthy skin and is applied in an outpatient dermatology setting, enabling dermatologists and oncology clinics to treat eligible patients for localized non-melanoma skin cancers with reduced procedural complexity, pain, side effects, and cosmetic impact.
- Sector
- Healthcare
- HQ
- Centennial, CO, United States
- Founded
- 2024
- Website
- oncopatch.com/
- Ownership
- Privately Held (backing)
OncoPatch doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoPatch shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoPatch in its N-PORT filings yet. We sweep new filings monthly.